Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Kineret

Phase 2Small molecule

Kineret is one of 12 small molecule programs targeting LAM. It is currently in Phase 2.

1

Indications

11

Total Trials

1

Active Trials

11

Competitors

Pipeline

Status by Indication[3][1]

Indication

LAMRecruiting

LAMPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in LAM

#DrugCompanyPhaseTrials

Kesimpta

Rituxan

Budesonide/formoterol

Humira

Boehringer Ingelheim

Cosentyx

Johnson & Johnson

Kineret

Stelara

BBiocon Biologics UK PLC

Roactemra

KKarolinska Institutet

Colesevelam Hcl

NAGLAZYME

BioMarin Pharmaceutical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Mediterranean Fever1 trial

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Completed·SSheba Medical Center·Phase 3·NCT01705756·25 enrolled

Chronic Lymphocytic Leukemia1 trial

Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients

Unknown status·—·Phase 1·NCT04691765·12 enrolled

Macrophage Activation Syndrome1 trial

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT02780583·9 enrolled

LAM1 trial

Personalized Therapies in Inflammatory Complex Disease

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03651518·32 enrolled

Type 1 Diabetes Mellitus1 trial

Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus

Unknown status·RRadboud University Medical Center·Phase 2·NCT01285245·16 enrolled

6 more indications

Chronic Granulomatous Disease1 trial

IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

Completed·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 1·NCT04136028·13 enrolled

Dialysis Patients1 trial

Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients

Completed·VVanderbilt University·N/A·NCT00420290·31 enrolled

GIST1 trial

REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

Completed· Amgen logo

Amgen··NCT00121056

Double-blind1 trial

A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

Completed·HHandok Inc.·Phase 1·NCT02175056·58 enrolled

Familial cold urticaria1 trial

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

Completed·NNova Scotia Health Authority·Phase 1·NCT00214851·8 enrolled

Rheumatoid Arthritis1 trial

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire

Completed· Amgen logo

Amgen·Phase 4·NCT00121043

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Kineret. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kineret compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kineret. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Amgen

Related News